Given the growing use of GLP-1 RA in both diabetic and non-diabetic populations (e.g., for obesity management), it is important to critically evaluate their potential association with cancer risk. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.